What's new?

Sofinnova Partners closes €445M ($540M) oversubscribed late-stage healthcare crossover fund

The pioneering growth capital fund is the largest dedicated to biopharma and medtech companies seeking scale-up financing in Europe With over €2 billion under management, Sofinnova Partners continues its expansion across the entire value chain of life sciences investments, from seed to later-stage PARIS, France – M...

TISSIUM Raises €50M in Series C Financing to Propel its Platform to Commercial Stage

Paris, France, August 31, 2021 - TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has closed a Series C round of financing, raising €50 million from new and existing international investors. Cathay Health, affiliated to global investment ...

Sofinnova Partners Closes €63M ($75M) Oversubscribed Medtech Acceleration Fund

Capital raise enables Sofinnova MD Start’s pioneering team to further support clinicians in transforming innovative ideas into medical realities Paris – July 13, 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the final close of its ...

Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases

• Financing co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB • Developing small molecules to repair neuronal dysfunction and resolve neuroinflammation • Innovative drug discov...

Micropep Raises EUR 8.5M (USD 10M) in oversubscribed Series A Financing to develop innovative small peptide solutions for agriculture

- Financing will be used to further develop proprietary discovery platform and progress pipeline targeting disease control and weed suppression - Company well positioned to enter and transform the EUR 47 billion-plus market for pesticides, initially targeting $28 billion herbicides and fungicides markets in America...

Biotalys announces successful €54.6 million Initial Public Offering

Ghent, BELGIUM – 01 July 2021 – Biotalys NV (“Biotalys” or the “Company”) an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions for a more sustainable and safer food supply, today announces the results of its initial public offering of n...

Mnemo Therapeutics Announces €75 million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platform

Financing led by Casdin Capital, Sofinnova Partners - initial seed investor, and an undisclosed investor Mnemo delivers epigenetic antigens, stronger T cells and best-in-class manufacturing established with groundbreaking research from Institut Curie and Memorial Sloan Kettering Paris, France, June 16, 2021 – Mnemo...

EnginZyme awarded as Technology Pioneer 2021 by World Economic Forum

STOCKHOLM, 15 June 2021 – EnginZyme, enabling the future of sustainable chemical production, announces that the World Economic Forum has selected it as one of the 2021 Technology Pioneers. This prestigious recognition highlights the company’s innovations that address the challenges of the chemical industry in the 2...

GenSight Biologics Announces Nature Medicine Case Report Showing Visual Recovery after GS030 Optogenetic Treatment

Paris, France, May 25, 2021, 7:30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the highly...

Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3

PARIS, France, May 24, 2021 – 6:30 pm (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces positive phase 2b clinical induction and p...

Avantium reaches key commercial milestone for its FDCA flagship plant with commitments for >50% of its output

AMSTERDAM, 7 April 2021, 18:00 hrs CEST – Avantium N.V., a leading technology company in renewable chemistry, announces that it has signed a conditional offtake agreement with Resilux, an international rigid plastic packaging supplier, for the supply of PEF resin from the planned Avantium FDCA flagship plant. This ...

1 2 3 ... 10